This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
Nature chemical biology · 2022
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
JCI insight · 2021
Latest funding
- $1,032,750
Environmental vulnerabilities of CD8 T cell responses
CIHR · 2025 · Co-investigator
- $1,136,025
Targeting drug tolerant persister cells in poor outcome breast cancer
CIHR · 2024 · Co-investigator
- $65,000
Investigating the Role of Bromodomain Proteins in Breast Cancer Chemotherapy Response
CIHR · 2024 · Nominated PI
2 publications.
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J
Environmental vulnerabilities of CD8 T cell responses
Principal investigators: Blagih, Julianna
Keywords: Cd8 T Cells; Cellular Metabolism; Differentiation; Epigenetic; Evironmental Exposures; Listeria Monocytogenes; Metabolomics; Mitochondria; Sucralose; T Cell Memory
Targeting drug tolerant persister cells in poor outcome breast cancer
Principal investigators: Park, Morag
Keywords: Bioinformatics; Chemotherapy-Induced Senescence; Drug Tolerant Persistor Cells; Epigenetics; Patient Derived Xenografts; Patient Minimal Residual Disease; Residual Disease; Spatial Transcriptomics; Triple Negative Breast Cancer
Investigating the Role of Bromodomain Proteins in Breast Cancer Chemotherapy Response
Principal investigators: Deblois, Genevieve
Keywords: Breast Cancer
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Principal investigators: Meloche, Sylvain
Keywords: Basal-Like Breast Cancer; Chemoresistance; Erk3; Genetically-Engineered Mouse Models; Hypoxia; Map Kinases; Metastasis; Proteomics; Signal Transduction; Transcriptomics
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Principal investigators: Meloche, Sylvain
Keywords: Basal-Like Breast Cancer; Chemoresistance; Erk3; Genetically-Engineered Mouse Models; Genomics; Hypoxia; Map Kinases; Metastasis; Proteomics; Signal Transduction
Prize - 202109PJT - Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Principal investigators: Deblois, Genevieve
Keywords: Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Cancer Therapy; Chromatin Accessibility; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification; Triple-Negative Breast Cancer
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Principal investigators: Deblois, Genevieve
Keywords: Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Cancer Therapy; Chromatin Accessibility; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification; Triple-Negative Breast Cancer
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Principal investigators: Deblois, Genevieve
Keywords: Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Cancer Therapy; Chromatin Accessibility; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification; Triple-Negative Breast Cancer
Investigating intra-tumour metabolic heterogeneity in triple-negative breast cancer
Principal investigators: Fukano, Marina
Keywords: Epigenetic Reprogramming; Glucose Transporter 1; Glutamine Synthetase; Intra-Tumour Heterogeneity; Metabolic Adaptation; Patient-Derived Xenografts; Spatial Transcriptomics; Triple-Negative Breast Cancer
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Principal investigators: Deblois, Genevieve
Keywords: Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Radiation Oncology/Medical Physics
- Anatomy and Cell Biology
- Pharmacology and Toxicology
- Medical Biophysics
- Oncology
- Other
Co-authors at Université de Montréal, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Dalia Barsyte-Lovejoy
Pharmacology and Toxicology
1 shared papers, latest 2022
Michael Witcher
Oncology
1 shared papers, latest 2021
Mathieu Lupien
Medical Biophysics
1 shared papers, latest 2022
Chantal Autexier
Anatomy and Cell Biology
1 shared papers, latest 2021
Benjamin Haibe-Kains
Radiation Oncology/Medical Physics
1 shared papers, latest 2022
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.